Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible staphylococcus aureus bacteremia

Erlinda R. Ulloa, Kavindra V. Singh, Matthew Geriak, Fadi Haddad, Barbara E. Murray, Victor Nizet, George Sakoulas

Research output: Contribution to journalArticlepeer-review

Abstract

Cefazolin and ertapenem combination therapy was used successfully to salvage 11 cases (6 endocarditis) of persistent methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (≤24 hours) in 8 cases. While in vitro synergy was modest, cefazolin plus ertapenem exhibited synergistic action in a rat model of MSSA endocarditis. The combination of cefazolin and ertapenem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants further clinical study in the treatment of refractory MSSA bacteremia and endocarditis.

Original languageEnglish (US)
Pages (from-to)1413-1418
Number of pages6
JournalClinical Infectious Diseases
Volume71
Issue number6
DOIs
StatePublished - Sep 15 2020

Keywords

  • Bacteremia
  • Cefazolin
  • Endocarditis
  • Ertapenem
  • Staphylococcus aureus

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Cefazolin and ertapenem salvage therapy rapidly clears persistent methicillin-susceptible staphylococcus aureus bacteremia'. Together they form a unique fingerprint.

Cite this